$1.40
-0.04-2.78%
At Close: -
$1.38
-0.02-1.43%
After Hours: 6:21 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Akebia Therapeutics (NASDAQ:AKBA) Stock, Analyst Ratings, Price Targets, Forecasts
Akebia Therapeutics Inc has a consensus price target of $4.67 based on the ratings of 7 analysts. The high is $10 issued by HC Wainwright & Co. on November 11, 2021. The low is $2 issued by Needham on May 9, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and BTIG on March 28, 2024, March 15, 2024, and November 29, 2023, respectively. With an average price target of $5 between HC Wainwright & Co., HC Wainwright & Co., and BTIG, there's an implied 262.32% upside for Akebia Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
BTIG
Piper Sandler
Needham
Mizuho
1calculated from analyst ratings
Analyst Ratings for Akebia Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/28/2024 | Buy Now | 334.78% | HC Wainwright & Co. | Ed Arce | $5 → $6 | Maintains | Buy | Get Alert |
| 03/15/2024 | Buy Now | 262.32% | HC Wainwright & Co. | Ed Arce | → $5 | Reiterates | Buy → Buy | Get Alert |
| 11/29/2023 | Buy Now | 189.86% | BTIG | Julian Harrison | → $4 | Assumes | → Buy | Get Alert |
| 11/17/2023 | Buy Now | 262.32% | HC Wainwright & Co. | Ed Arce | $3.75 → $5 | Maintains | Buy | Get Alert |
| 09/27/2023 | Buy Now | 171.74% | HC Wainwright & Co. | Ed Arce | → $3.75 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2023 | Buy Now | 171.74% | HC Wainwright & Co. | Ed Arce | $2 → $3.75 | Upgrade | Neutral → Buy | Get Alert |
| 08/11/2023 | Buy Now | 44.93% | HC Wainwright & Co. | Ed Arce | → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 06/21/2023 | Buy Now | 44.93% | HC Wainwright & Co. | Ed Arce | → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 06/14/2023 | Buy Now | 44.93% | HC Wainwright & Co. | Ed Arce | → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 06/02/2023 | Buy Now | 44.93% | HC Wainwright & Co. | Ed Arce | → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 05/31/2023 | Buy Now | 189.86% | Piper Sandler | Christopher Raymond | $2 → $4 | Upgrade | Neutral → Overweight | Get Alert |
| 05/30/2023 | Buy Now | 44.93% | HC Wainwright & Co. | Ed Arce | → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 05/26/2023 | Buy Now | 44.93% | HC Wainwright & Co. | Ed Arce | → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 05/09/2023 | Buy Now | 44.93% | Needham | Ed Arce | → $2 | Reiterates | → Neutral | Get Alert |
| 04/26/2023 | Buy Now | 44.93% | HC Wainwright & Co. | Ed Arce | $1.25 → $2 | Maintains | Neutral | Get Alert |
| 03/31/2023 | Buy Now | -9.42% | HC Wainwright & Co. | Ed Arce | → $1.25 | Reiterates | → Neutral | Get Alert |
| 03/10/2023 | Buy Now | -9.42% | HC Wainwright & Co. | Ed Arce | → $1.25 | Reiterates | → Neutral | Get Alert |
| 02/22/2023 | Buy Now | -9.42% | HC Wainwright & Co. | Ed Arce | → $1.25 | Maintains | Neutral | Get Alert |
| 05/16/2022 | Buy Now | -9.42% | HC Wainwright & Co. | Ed Arce | $2 → $1.25 | Maintains | Neutral | Get Alert |
| 03/31/2022 | Buy Now | 44.93% | HC Wainwright & Co. | Ed Arce | $10 → $2 | Downgrade | Buy → Neutral | Get Alert |
| 03/31/2022 | Buy Now | — | Needham | Serge Belanger | — | Downgrade | Buy → Hold | Get Alert |
| 03/31/2022 | Buy Now | 44.93% | Mizuho | Difei Yang | $6 → $2 | Downgrade | Buy → Neutral | Get Alert |
| 03/31/2022 | Buy Now | 44.93% | Piper Sandler | Christopher Raymond | $8 → $2 | Downgrade | Overweight → Neutral | Get Alert |
| 11/11/2021 | Buy Now | 624.64% | HC Wainwright & Co. | — | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Akebia Therapeutics (AKBA) stock?
The latest price target for Akebia Therapeutics (NASDAQ:AKBA) was reported by HC Wainwright & Co. on March 28, 2024. The analyst firm set a price target for $6.00 expecting AKBA to rise to within 12 months (a possible 334.78% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Akebia Therapeutics (AKBA)?
The latest analyst rating for Akebia Therapeutics (NASDAQ:AKBA) was provided by HC Wainwright & Co., and Akebia Therapeutics maintained their buy rating.
When was the last upgrade for Akebia Therapeutics (AKBA)?
The last upgrade for Akebia Therapeutics Inc happened on August 28, 2023 when HC Wainwright & Co. raised their price target to $3.75. HC Wainwright & Co. previously had a neutral for Akebia Therapeutics Inc.
When was the last downgrade for Akebia Therapeutics (AKBA)?
The last downgrade for Akebia Therapeutics Inc happened on March 31, 2022 when HC Wainwright & Co. changed their price target from $10 to $2 for Akebia Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Akebia Therapeutics (AKBA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akebia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akebia Therapeutics was filed on March 28, 2024 so you should expect the next rating to be made available sometime around March 28, 2025.
Is the Analyst Rating Akebia Therapeutics (AKBA) correct?
While ratings are subjective and will change, the latest Akebia Therapeutics (AKBA) rating was a maintained with a price target of $5.00 to $6.00. The current price Akebia Therapeutics (AKBA) is trading at is $1.38, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.